S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Technical issues at Lufthansa cause delays in Frankfurt
Travel disruption hits Germany on eve of transport strike
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Technical issues at Lufthansa cause delays in Frankfurt
Travel disruption hits Germany on eve of transport strike
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Technical issues at Lufthansa cause delays in Frankfurt
Travel disruption hits Germany on eve of transport strike
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Technical issues at Lufthansa cause delays in Frankfurt
Travel disruption hits Germany on eve of transport strike
NASDAQ:MASI

Masimo - MASI Competitors

$172.88
-1.54 (-0.88%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$172.34
$174.15
50-Day Range
$156.75
$182.43
52-Week Range
$108.89
$184.96
Volume
150,703 shs
Average Volume
362,754 shs
Market Capitalization
$9.09 billion
P/E Ratio
66.49
Dividend Yield
N/A
Price Target
$182.00

MASI vs. ITGR, CNMD, INMD, TMDX, LIVN, NBIX, RDY, JAZZ, RGEN, and OSH

Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include Integer (ITGR), CONMED (CNMD), InMode (INMD), TransMedics Group (TMDX), LivaNova (LIVN), Neurocrine Biosciences (NBIX), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), Repligen (RGEN), and Oak Street Health (OSH). These companies are all part of the "medical" sector.

Masimo vs.

Integer (NYSE:ITGR) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.

Masimo has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.38 billion1.85$66.38 million$1.9838.72
Masimo$2.04 billion4.47$143.50 million$2.6066.49

In the previous week, Masimo had 10 more articles in the media than Integer. MarketBeat recorded 14 mentions for Masimo and 4 mentions for Integer. Masimo's average media sentiment score of 0.54 beat Integer's score of 0.27 indicating that Masimo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integer
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Masimo
4 Very Positive mention(s)
5 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

98.4% of Integer shares are owned by institutional investors. Comparatively, 87.7% of Masimo shares are owned by institutional investors. 2.0% of Integer shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Integer currently has a consensus target price of $87.00, indicating a potential upside of 13.47%. Masimo has a consensus target price of $182.00, indicating a potential upside of 5.28%. Given Integer's stronger consensus rating and higher probable upside, analysts clearly believe Integer is more favorable than Masimo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integer
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Masimo
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Masimo received 80 more outperform votes than Integer when rated by MarketBeat users. Likewise, 66.37% of users gave Masimo an outperform vote while only 64.10% of users gave Integer an outperform vote.

CompanyUnderperformOutperform
IntegerOutperform Votes
366
64.10%
Underperform Votes
205
35.90%
MasimoOutperform Votes
446
66.37%
Underperform Votes
226
33.63%

Integer has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Masimo has a net margin of 7.06% compared to Integer's net margin of 4.82%. Masimo's return on equity of 18.84% beat Integer's return on equity.

Company Net Margins Return on Equity Return on Assets
Integer 4.82% 9.42% 4.75%
Masimo 7.06% 18.84% 9.09%

Summary

Masimo beats Integer on 14 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MASI vs. The Competition

MetricMasimoElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$9.17B$3.33B$4.35B$5.88B
Dividend YieldN/A1.49%2.32%4.53%
P/E Ratio66.498.8968.1711.18
Price / Sales4.4736.863,460.5556.13
Price / Cash23.4819.8027.62104.20
Price / Book6.793.114.454.93
Net Income$143.50M$115.47M$114.96M$190.66M
7 Day Performance0.67%2.51%-0.85%0.68%
1 Month Performance4.09%-4.58%-6.62%-6.00%
1 Year Performance12.27%27.12%-16.08%-18.29%

Masimo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ITGR
Integer
2.0646 of 5 stars
$74.16
-0.3%
$87.00
+17.3%
-2.5%$2.47B$1.38B37.4510,000
CNMD
CONMED
2.129 of 5 stars
$96.84
+2.6%
$120.00
+23.9%
N/A$2.95B$1.05B-34.103,800Analyst Report
News Coverage
INMD
InMode
2.3675 of 5 stars
$30.48
-3.5%
$46.33
+52.0%
-19.9%$2.63B$454.27M16.04362Positive News
TMDX
TransMedics Group
1.9315 of 5 stars
$74.31
-1.7%
$71.57
-3.7%
+208.3%$2.39B$93.46M-59.45148Positive News
LIVN
LivaNova
2.2178 of 5 stars
$43.46
-0.5%
$76.20
+75.3%
-46.7%$2.33B$1.02B-26.832,900
NBIX
Neurocrine Biosciences
3.3189 of 5 stars
$95.15
-1.3%
$125.65
+32.1%
+3.6%$9.19B$1.49B62.191,200
RDY
Dr. Reddy's Laboratories
1.9804 of 5 stars
$54.36
0.0%
$67.00
+23.3%
-2.6%$9.06B$237.28B20.1324,795
JAZZ
Jazz Pharmaceuticals
2.9709 of 5 stars
$138.46
-0.9%
$204.27
+47.5%
-12.1%$8.77B$3.66B-39.002,800Positive News
RGEN
Repligen
2.5322 of 5 stars
$166.25
-4.5%
$216.86
+30.4%
-11.2%$9.67B$801.54M51.152,025
OSH
Oak Street Health
1.7155 of 5 stars
$35.41
-1.0%
$33.27
-6.1%
+38.9%$8.64B$2.16B-16.026,000Analyst Downgrade
Insider Selling
This page (NASDAQ:MASI) was last updated on 3/26/2023 by MarketBeat.com Staff